Cargando…
A prognostic systemic inflammation score (SIS) in patients with advanced intrahepatic cholangiocarcinoma
PURPOSE: Systemic-inflammatory response parameters (SIR) are known prognostic markers in different tumour entities, but have not been evaluated in patients with iCCA treated with systemic chemotherapy. Therefore, we evaluated the impact of different SIR markers on the clinical course of patients wit...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349723/ https://www.ncbi.nlm.nih.gov/pubmed/36334155 http://dx.doi.org/10.1007/s00432-022-04424-0 |
_version_ | 1785073981068410880 |
---|---|
author | Maßmann, M. Treckmann, J. Markus, P. Schumacher, B. Albers, D. Ting, S. Mende, B. Roehrle, J. Virchow, I. Rosery, V. Laue, K. Zaun, G. Kostbade, K. Pogorzelski, M. Schmid, K. W. Baba, H. Siveke, J. T. Paul, A. Schildhaus, H. U. Schuler, M. Wiesweg, M. Kasper, S. |
author_facet | Maßmann, M. Treckmann, J. Markus, P. Schumacher, B. Albers, D. Ting, S. Mende, B. Roehrle, J. Virchow, I. Rosery, V. Laue, K. Zaun, G. Kostbade, K. Pogorzelski, M. Schmid, K. W. Baba, H. Siveke, J. T. Paul, A. Schildhaus, H. U. Schuler, M. Wiesweg, M. Kasper, S. |
author_sort | Maßmann, M. |
collection | PubMed |
description | PURPOSE: Systemic-inflammatory response parameters (SIR) are known prognostic markers in different tumour entities, but have not been evaluated in patients with iCCA treated with systemic chemotherapy. Therefore, we evaluated the impact of different SIR markers on the clinical course of patients with advanced iCCA treated at our center. METHODS: SIR markers were retrospectively evaluated in 219 patients with iCCA at the West-German-Cancer-Center Essen from 2014 to 2019. Markers included neutrophil/lymphocyte ratio (NLR), lymphocyte/monocyte ratio (LMR), CRP, and the modified Glasgow-Prognostic-Score (mGPS), which were correlated with clinico-pathological findings, response to chemotherapy (ORR), progression-free (PFS) and overall survival (OS) using Kaplan–Meier analyses, and Cox proportional models. RESULTS: Median overall survival (OS) of the entire cohort was 14.8 months (95% CI 11.2–24.4). Median disease-free survival (DFS) in 81 patients undergoing resection was 12.3 months (95% CI 9.7–23.1). The median OS from start of palliative CTX (OS(pall)) was 10.9 months (95% 9.4–14.6). A combined Systemic Inflammatory Score (SIS) comprising all evaluated SIR markers correlated significantly with ORR, PFS, and OS(pall). Patients with a high SIS (≥ 2) vs. SIS 0 had a significantly inferior OS(pall) (HR 8.7 95% CI 3.71–20.38, p < 0.001). Multivariate analysis including known prognostic markers (ECOG, CA19-9, LDH, and N- and M-status) identified the SIS as an independent prognostic factor. CONCLUSIONS: Inflammatory markers associate with inferior survival outcomes in patients with iCCA. A simple SIS may guide treatment decisions in patients treated with systemic chemotherapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00432-022-04424-0. |
format | Online Article Text |
id | pubmed-10349723 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-103497232023-07-17 A prognostic systemic inflammation score (SIS) in patients with advanced intrahepatic cholangiocarcinoma Maßmann, M. Treckmann, J. Markus, P. Schumacher, B. Albers, D. Ting, S. Mende, B. Roehrle, J. Virchow, I. Rosery, V. Laue, K. Zaun, G. Kostbade, K. Pogorzelski, M. Schmid, K. W. Baba, H. Siveke, J. T. Paul, A. Schildhaus, H. U. Schuler, M. Wiesweg, M. Kasper, S. J Cancer Res Clin Oncol Research PURPOSE: Systemic-inflammatory response parameters (SIR) are known prognostic markers in different tumour entities, but have not been evaluated in patients with iCCA treated with systemic chemotherapy. Therefore, we evaluated the impact of different SIR markers on the clinical course of patients with advanced iCCA treated at our center. METHODS: SIR markers were retrospectively evaluated in 219 patients with iCCA at the West-German-Cancer-Center Essen from 2014 to 2019. Markers included neutrophil/lymphocyte ratio (NLR), lymphocyte/monocyte ratio (LMR), CRP, and the modified Glasgow-Prognostic-Score (mGPS), which were correlated with clinico-pathological findings, response to chemotherapy (ORR), progression-free (PFS) and overall survival (OS) using Kaplan–Meier analyses, and Cox proportional models. RESULTS: Median overall survival (OS) of the entire cohort was 14.8 months (95% CI 11.2–24.4). Median disease-free survival (DFS) in 81 patients undergoing resection was 12.3 months (95% CI 9.7–23.1). The median OS from start of palliative CTX (OS(pall)) was 10.9 months (95% 9.4–14.6). A combined Systemic Inflammatory Score (SIS) comprising all evaluated SIR markers correlated significantly with ORR, PFS, and OS(pall). Patients with a high SIS (≥ 2) vs. SIS 0 had a significantly inferior OS(pall) (HR 8.7 95% CI 3.71–20.38, p < 0.001). Multivariate analysis including known prognostic markers (ECOG, CA19-9, LDH, and N- and M-status) identified the SIS as an independent prognostic factor. CONCLUSIONS: Inflammatory markers associate with inferior survival outcomes in patients with iCCA. A simple SIS may guide treatment decisions in patients treated with systemic chemotherapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00432-022-04424-0. Springer Berlin Heidelberg 2022-11-05 2023 /pmc/articles/PMC10349723/ /pubmed/36334155 http://dx.doi.org/10.1007/s00432-022-04424-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Maßmann, M. Treckmann, J. Markus, P. Schumacher, B. Albers, D. Ting, S. Mende, B. Roehrle, J. Virchow, I. Rosery, V. Laue, K. Zaun, G. Kostbade, K. Pogorzelski, M. Schmid, K. W. Baba, H. Siveke, J. T. Paul, A. Schildhaus, H. U. Schuler, M. Wiesweg, M. Kasper, S. A prognostic systemic inflammation score (SIS) in patients with advanced intrahepatic cholangiocarcinoma |
title | A prognostic systemic inflammation score (SIS) in patients with advanced intrahepatic cholangiocarcinoma |
title_full | A prognostic systemic inflammation score (SIS) in patients with advanced intrahepatic cholangiocarcinoma |
title_fullStr | A prognostic systemic inflammation score (SIS) in patients with advanced intrahepatic cholangiocarcinoma |
title_full_unstemmed | A prognostic systemic inflammation score (SIS) in patients with advanced intrahepatic cholangiocarcinoma |
title_short | A prognostic systemic inflammation score (SIS) in patients with advanced intrahepatic cholangiocarcinoma |
title_sort | prognostic systemic inflammation score (sis) in patients with advanced intrahepatic cholangiocarcinoma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349723/ https://www.ncbi.nlm.nih.gov/pubmed/36334155 http://dx.doi.org/10.1007/s00432-022-04424-0 |
work_keys_str_mv | AT maßmannm aprognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT treckmannj aprognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT markusp aprognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT schumacherb aprognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT albersd aprognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT tings aprognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT mendeb aprognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT roehrlej aprognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT virchowi aprognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT roseryv aprognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT lauek aprognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT zaung aprognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT kostbadek aprognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT pogorzelskim aprognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT schmidkw aprognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT babah aprognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT sivekejt aprognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT paula aprognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT schildhaushu aprognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT schulerm aprognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT wieswegm aprognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT kaspers aprognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT maßmannm prognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT treckmannj prognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT markusp prognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT schumacherb prognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT albersd prognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT tings prognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT mendeb prognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT roehrlej prognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT virchowi prognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT roseryv prognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT lauek prognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT zaung prognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT kostbadek prognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT pogorzelskim prognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT schmidkw prognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT babah prognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT sivekejt prognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT paula prognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT schildhaushu prognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT schulerm prognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT wieswegm prognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma AT kaspers prognosticsystemicinflammationscoresisinpatientswithadvancedintrahepaticcholangiocarcinoma |